UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 (State or other jurisdiction of incorporation or organization) 2403 Sidn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 (State or other jurisdiction of incorporation or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41479 Delaware 47-4752305 (State or other jurisdiction of incorporation or organization) REBORN COFFEE, INC. (Exact name of Registr ...

Exhibit 99.1 PRESS RELEASE XWELL Reports Second Quarter 2025 Results NEW YORK — August 14, 2025 – XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced results for the second quarter ended June 30, 2025. From providing critical biosecurity support to building tech-forward wellness spaces in transportation hubs and local communities, XWELL currently is on a growth trajectory. Through its portfolio of in-airport and off-airport br ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Tampa, FL 33612 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (813) 875-6600 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37823 TUHURA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 99-0360497 ( State or other jurisdict ...

Exhibit 99.1 Nuvve Provides Second Quarter 2025 Financial Update Investor Conference Call to be Held Today at 5:00 PM Eastern Time (2:00 PM PT) SAN DIEGO, August 14, 2025 /PRNewswire/— Nuvve Holding Corp. ("Nuvve", "we", the "Company") (Nasdaq: NVVE), a green energy technology company that provides a globally-available, commercial vehicle-to-grid (V2G) technology platform that enables electric vehicle (EV) batteries to store and resell unused energy back to the local electric grid and provides other grid se ...

收入和利润（同比环比） - 2025年第二季度收入为166.63万美元，同比下降16%，主要由于州和地方政府对应急准备服务的需求减少[109][110] - 2025年上半年净亏损达264.2万美元，同比扩大1264%，运营亏损增长1097%至264.49万美元[109] 成本和费用（同比环比） - 2025年上半年毛利率为125.7万美元，同比下降25%，成本下降11%至185.87万美元[109][111] - 2025年第二季度销售及行政费用激增87%至204.65万美元，主要因IPO相关咨询费增加11.16万美元及营销投入增长16.4万美元[109][112] 现金流表现 - 2025年上半年经营活动现金净流出212.5万美元，主要因净亏损扩大及库存减少3.91万美元[117][118] - 2025年投资活动现金流出44.75万美元，主要用于新总部租赁改良[117][119] - 2025年上半年融资活动现金流入469.87万美元，主要来自IPO及超额配售净收益468万美元[117][120] 现金及等价物 - 截至2025年6月30日现金及等价物为422.42万美元，较2024年同期增长128.6%[116] 融资活动 - 公司于2025年7月签署2500万美元股权融资协议，可分批出售普通股，定价为测量期最低日均价的95%[114][115] 业务季节性特征 - 公司业务呈现季节性特征，第三和第四季度通常为收入高峰，冬季运营成本因天气因素较高[108]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41615 Mangoceuticals, Inc. (Exact name of Registrant as specified in its charter) Texas 87-3841292 (State or other jurisdiction ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission file number 001-41765 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 MIRA Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Florida 85-33 ...